A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Not Recently Received or Have Not Received Complement Inhibitor Treatment
This research study is investigating a new combination of two medications, pozelimab and cemdisiran, for adults living with a rare blood disorder called Paroxysmal Nocturnal Hemoglobinuria (PNH). The main goals are to find out how safe this new combination is and how well it works. We're also comparing its effects to two established PNH treatments, ravulizumab and eculizumab. Participants are adults who haven't recently received or have never had treatment with complement inhibitor medicines for their PNH. The study will help us understand side effects, how the body handles these new drugs, and whether the body might make antibodies against them, which could affect their usefulness.
एक नजर में
यह अध्ययन किस बारे में है?
This study is exploring potential new treatments for a rare blood condition called Paroxysmal Nocturnal Hemoglobinuria, often shortened to PNH. PNH causes red blood cells to break down too early, leading to symptoms like tiredness, anaemia, and sometimes blood clots. Currently, there are treatments available, but researchers are always looking for new and potentially better options.
This particular study is focusing on a new combination of two experimental drugs called pozelimab and cemdisiran. The main purpose is to see how safe this combination is for people with PNH and how effectively it helps manage their condition. To understand its benefits, the study will compare this new combination with two existing and commonly used PNH treatments: ravulizumab and eculizumab.
By comparing these treatments, the study aims to answer important questions. We want to know if the new pozelimab and cemdisiran combination is as good as, or even better than, the current treatments. Researchers will also be carefully monitoring for any side effects and learning how the body processes these new medications. This helps us understand if the new treatment could be a valuable option for future PNH patients.
मुख्य निष्कर्ष
- This study investigates a new combination treatment for PNH.
- It compares new drugs (pozelimab + cemdisiran) with existing PNH treatments.
- Safety and effectiveness for adults with PNH are key goals.
- भागीदारी में नियमित क्लिनिक दौरे और स्वास्थ्य जांच शामिल हैं।.
- Meningitis vaccinations are a crucial eligibility requirement.
कौन पात्र हो सकता है?
To join this study, you must be an adult (18 years or older) with PNH that has been officially diagnosed through special blood tests. Your PNH needs to be 'active,' meaning you're currently experiencing symptoms or signs of the condition, and certain blood levels (LDH level) must be above a specific point.
You also need to be able to attend all the study appointments, whether they are in person or online. It's very important that you are willing and able to get specific meningitis vaccinations, if you haven't had them already, as required by the study plan.
There are also reasons why you might not be able to join. For instance, if you've recently had certain PNH treatments (like eculizumab within the last 3 months, or ravulizumab within the last 6 months), or if you've had an organ or bone marrow transplant. You also can't participate if you weigh less than 40 kilograms, plan to use other PNH treatments not part of the study, or have certain infections.
क्या यह अध्ययन आपके लिए उपयुक्त हो सकता है?
यह देखने के लिए इन त्वरित प्रश्नों का उत्तर दें कि क्या आप पात्र हो सकते हैं। यह केवल एक मार्गदर्शिका है — अंतिम निर्णय शोध टीम द्वारा लिया जाता है।.
- क्या आप वयस्क हैं (18 वर्ष या उससे अधिक)?
- Have you been diagnosed with PNH?
- Are you experiencing active PNH symptoms or signs?
- Are you willing and able to get meningitis vaccinations if needed?
- Have you not recently received specific PNH complement inhibitor treatments (e.g., eculizumab in last 3 months, ravulizumab in last 6 months)?
- Have you NOT had an organ or bone marrow transplant?
भागीदारी में क्या शामिल है?
If you decide to take part in this study, you will likely receive either the new drug combination (pozelimab + cemdisiran) or one of the existing PNH treatments (ravulizumab or eculizumab). These will be given over a period of time as determined by the study. You will have regular visits, which might be in person at a clinic or sometimes done remotely. During these visits, the study team will carry out health checks, take blood samples to see how the treatment is working, and ask about any side effects you might be experiencing. They will also look at how much medication is in your blood and if your body is making antibodies against the study drugs. The total duration of your participation in the study, including follow-up, will be explained in detail by the study team.
संभावित जोखिम और लाभ
स्थान (68)
- The Oncology Institute of Hope & Innovationसत्यापित पोस्टकोडव्हिटियर, संयुक्त राज्य अमेरिका
- Centro de Estudos e Pesquisas em Hematologia e Oncologiaसत्यापित पोस्टकोडSanto André, Brazil
- A Beneficencia Portuguesa de Sao Paulo, BP Miranteसत्यापित पोस्टकोडसाओ पाउलो, ब्राज़ील
- Casa de Saude Santa Marcelinaसत्यापित पोस्टकोडसाओ पाउलो, ब्राज़ील
- टोरंटो जनरल अस्पतालसत्यापित पोस्टकोडटोरंटो, कनाडा
- पेकिंग यूनियन मेडिकल कॉलेज अस्पतालसत्यापित पोस्टकोडबीजिंग, चीन
- Hospital Pablo Tobon Uribeसत्यापित पोस्टकोडMedellín, Colombia
- George Papanikolaou Hospitalसत्यापित पोस्टकोडThessaloniki, Greece
- Semmelweis Universityसत्यापित पोस्टकोडबुडापेस्ट, हंगरी
- Malabar Cancer Center, Keralaसत्यापित पोस्टकोडKannur, India
- Amrita Institute of Medical Sciences (AIMS) and Research Centre Aimsसत्यापित पोस्टकोडKochi, India
- K J Somaiya Super Specialty Hospital & Research Centreसत्यापित पोस्टकोडMumbai, India
सामान्य प्रश्न
PNH क्या है?
PNH stands for Paroxysmal Nocturnal Hemoglobinuria. It's a rare blood condition where red blood cells break down too quickly, which can cause symptoms like tiredness.
Are the new drugs safe?
The study aims to find out how safe the new drug combination, pozelimab and cemdisiran, is. All study medications are carefully monitored for any side effects.
Will I get the new treatment or an existing one?
During the study, you will be given either the new combination treatment or one of two existing, approved treatments for PNH (ravulizumab or eculizumab).
मैं अध्ययन में कितने समय तक रहूँगा?
The exact length of your participation will be fully explained by the study team. It will involve regular visits and check-ups over a period of time.
क्या मैं किसी भी समय भाग लेना बंद कर सकता हूँ?
Yes, you have the right to leave the study at any point, for any reason, without it affecting your medical care.
और अधिक जानने के लिए कैसे पता करें
किसी अध्ययन में भाग लेने का निर्णय लेने से पहले हमेशा अपने जीपी या विशेषज्ञ से बात करें।.
चर्चा
समुदाय चर्चा
हमारे फोरम द्वारा संचालित community.patient.info. कृपया सम्मानजनक रहें — यह चिकित्सा सलाह नहीं है।.